Drug Profile
STM 434
Alternative Names: STM-434Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Amgen
- Developer Atara Biotherapeutics
- Class Antibodies; Antineoplastics; Recombinant fusion proteins
- Mechanism of Action Activin inhibitors; Type-II-B activin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ovarian cancer; Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Ovarian-cancer in USA (IV, Injection)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Injection)
- 13 Jan 2017 Santa Maria Biotherapeutics completes a phase I trial in Solid tumours and Ovarian cancer (Late-stage disease, Combination therapy) in USA (NCT02262455)